| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
1 Department of Cellular and Molecular Biology, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada; and 2 Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
The statin family of drugs are well-established inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase and are used clinically in the control of hypercholesterolemia. Recent evidence, from ourselves and others, shows that statins can also trigger tumor-specific apoptosis by blocking protein geranylgeranylation. We and others have proposed that statins disrupt localization and function of geranylgeranylated proteins responsible for activating signal transduction pathways essential for the growth and/or survival of transformed cells. To explore this further, we have investigated whether the mitogen-activated protein kinase (MAPK) signaling cascades play a role in regulating statin-induced apoptosis. Cells derived from acute myelogenous leukemia (AML) are used as our model system. We show that p38 and c-Jun NH2-terminal kinase/stress-activated kinase MAPK pathways are not altered during lovastatin-induced apoptosis. By contrast, exposure of primary and established AML cells to statins results in significant disruption of basal extracellular signal-regulated kinase (ERK) 1/2 phosphorylation. Addition of geranylgeranyl PPi reverses statin-induced loss of ERK1/2 phosphorylation and apoptosis. By establishing and evaluating the inducible Raf-1:ER system in AML cells, we show that constitutive activation of the Raf/MAPK kinase (MEK)/ERK pathway significantly represses but does not completely block lovastatin-induced apoptosis. Our results strongly suggest statins trigger apoptosis by regulating several signaling pathways, including the Raf/MEK/ERK pathway. Indeed, down-regulation of the Raf/MEK/ERK pathway potentiates statin-induced apoptosis because exposure to the MEK1 inhibitor PD98059 sensitizes AML cells to low, physiologically achievable concentrations of lovastatin. Our study suggests that lovastatin, alone or in combination with a MEK1 inhibitor, may represent a new and immediately available therapeutic approach to combat tumors with activated ERK1/2, such as AML.
This article has been cited by other articles:
![]() |
K. van der Weide, S. D.P.W.M. de Jonge-Peeters, F. Kuipers, E. G.E. de Vries, and E. Vellenga Combining Simvastatin with the Farnesyltransferase Inhibitor Tipifarnib Results in an Enhanced Cytotoxic Effect in a Subset of Primary CD34+ Acute Myeloid Leukemia Samples Clin. Cancer Res., May 1, 2009; 15(9): 3076 - 3083. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sassano, M. Lo Iacono, G. Antico, A. Jordan, S. Uddin, R. A. Calogero, and L. C. Platanias Regulation of leukemic cell differentiation and retinoid-induced gene expression by statins Mol. Cancer Ther., March 1, 2009; 8(3): 615 - 625. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Woodard, A. Sassano, N. Hay, and L. C. Platanias Statin-Dependent Suppression of the Akt/Mammalian Target of Rapamycin Signaling Cascade and Programmed Cell Death 4 Up-Regulation in Renal Cell Carcinoma Clin. Cancer Res., July 15, 2008; 14(14): 4640 - 4649. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hoque, H. Chen, and X.-c. Xu Statin Induces Apoptosis and Cell Growth Arrest in Prostate Cancer Cells Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 88 - 94. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zheng, X.-X. Cui, G. E. Avila, M.-T. Huang, Y. Liu, J. Patel, A. N. T. Kong, R. Paulino, W. J. Shih, Y. Lin, et al. Atorvastatin and Celecoxib Inhibit Prostate PC-3 Tumors in Immunodeficient Mice Clin. Cancer Res., September 15, 2007; 13(18): 5480 - 5487. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. W.-L. Wong, J. W. Clendening, A. Martirosyan, P. C. Boutros, C. Bros, F. Khosravi, I. Jurisica, A. K. Stewart, P. L. Bergsagel, and L. Z. Penn Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma Mol. Cancer Ther., June 1, 2007; 6(6): 1886 - 1897. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Dai, P. Khanna, S. Chen, X.-Y. Pei, P. Dent, and S. Grant Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation Blood, May 15, 2007; 109(10): 4415 - 4423. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sassano, E. Katsoulidis, G. Antico, J. K. Altman, A. J. Redig, S. Minucci, M. S. Tallman, and L. C. Platanias Suppressive Effects of Statins on Acute Promyelocytic Leukemia Cells Cancer Res., May 1, 2007; 67(9): 4524 - 4532. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. S. Ahn, G. Sethi, and B. B. Aggarwal Simvastatin Potentiates TNF-{alpha}-Induced Apoptosis through the Down-Regulation of NF-{kappa}B-Dependent Antiapoptotic Gene Products: Role of I{kappa}B{alpha} Kinase and TGF-beta-Activated Kinase-1 J. Immunol., February 15, 2007; 178(4): 2507 - 2516. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Yacoub, W. Hawkins, D. Hanna, H. Young, M. A. Park, M. Grant, J. D. Roberts, D. T. Curiel, P. B. Fisher, K. Valerie, et al. Human Chorionic Gonadotropin Modulates Prostate Cancer Cell Survival after Irradiation or HMG CoA Reductase Inhibitor Treatment Mol. Pharmacol., January 1, 2007; 71(1): 259 - 275. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Bissonauth, S. Roy, M. Gravel, S. Guillemette, and J. Charron Requirement for Map2k1 (Mek1) in extra-embryonic ectoderm during placentogenesis Development, September 1, 2006; 133(17): 3429 - 3440. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rahmani, E. M. Davis, C. Bauer, P. Dent, and S. Grant Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation J. Biol. Chem., October 21, 2005; 280(42): 35217 - 35227. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. S. Choi, B. Y. Choi, Y.-Y. Cho, F. Zhu, A. M. Bode, and Z. Dong Phosphorylation of Ser28 in Histone H3 Mediated by Mixed Lineage Kinase-like Mitogen-activated Protein Triple Kinase {alpha} J. Biol. Chem., April 8, 2005; 280(14): 13545 - 13553. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |